RPG Life Sciences Limited Stock Price Today (NSE: RPGLIFE)
Fundamental Score
RPG Life Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
RPG Life Sciences Limited share price today is ₹2739.10, up +0.75% on NSE/BSE as of 16 September 2026. RPG Life Sciences Limited (RPGLIFE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.53K (Cr). The 52-week high for RPGLIFE share price is ₹3082.00 and the 52-week low is ₹1733.00. At a P/E ratio of 37.86x, RPGLIFE is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 20.28% and a debt-to-equity ratio of 0.03.
RPG Life Sciences Limited Share Price Chart — NSE/BSE Historical Performance
RPG Life Sciences Limited share price chart: 5.49% return over the past month. 52-week high ₹3082.00, 52-week low ₹1733.00.
RPG Life Sciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2691.10 | ₹2760.00 | ₹2630.50 | ₹2739.10 | 14.16K (Cr) | |
| ₹2709.00 | ₹2918.20 | ₹2685.00 | ₹2718.80 | 60.66K (Cr) | |
| ₹2794.30 | ₹2794.30 | ₹2680.00 | ₹2698.60 | 17.82K (Cr) | |
| ₹2789.00 | ₹2844.00 | ₹2745.00 | ₹2782.70 | 11.65K (Cr) | |
| ₹2848.00 | ₹2961.90 | ₹2796.10 | ₹2812.00 | 51.22K (Cr) | |
| ₹2673.00 | ₹2870.00 | ₹2642.10 | ₹2802.60 | 28.31K (Cr) | |
| ₹2746.00 | ₹2781.10 | ₹2651.00 | ₹2673.40 | 13.62K (Cr) | |
| ₹2652.40 | ₹2739.00 | ₹2638.90 | ₹2721.60 | 20.46K (Cr) | |
| ₹2596.90 | ₹2698.90 | ₹2583.10 | ₹2652.40 | 25.74K (Cr) | |
| ₹2590.50 | ₹2591.30 | ₹2550.00 | ₹2564.90 | 7.01K (Cr) |
RPG Life Sciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2665.00 | ₹2961.90 | ₹2550.00 | ₹2739.10 | +2.78% | |
| ₹2780.00 | ₹2867.00 | ₹2490.10 | ₹2629.00 | -5.43% | |
| ₹2306.00 | ₹3082.00 | ₹2305.00 | ₹2768.20 | +20.04% | |
| ₹2224.00 | ₹2397.60 | ₹2065.30 | ₹2292.50 | +3.08% | |
| ₹2314.00 | ₹2524.90 | ₹2187.20 | ₹2224.70 | -3.86% | |
| ₹1941.10 | ₹2336.60 | ₹1840.40 | ₹2295.00 | +18.23% | |
| ₹1764.70 | ₹1985.00 | ₹1733.00 | ₹1857.70 | +5.27% | |
| ₹1981.00 | ₹2093.80 | ₹1864.00 | ₹1874.40 | -5.38% | |
| ₹2322.30 | ₹2357.90 | ₹1880.00 | ₹2007.90 | -13.54% | |
| ₹2297.40 | ₹2392.20 | ₹2175.00 | ₹2322.30 | +1.08% | |
| ₹2413.50 | ₹2480.00 | ₹2196.00 | ₹2278.10 | -5.61% | |
| ₹2234.20 | ₹2483.80 | ₹2210.80 | ₹2403.90 | +7.60% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
RPG Life Sciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
RPG Life Sciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of RPGLIFE across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (20.28%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (26.50%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (22.04%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (15.85%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.70% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (23.55% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (174.26x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.88)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹156.99 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (72.95%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
High Price-to-Book Ratio (8.54x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-5.66% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Limited Institutional Interest (FII+DII: 8.32%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
RPG Life Sciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare RPG Life Sciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
RPG Life Sciences LimitedRPG Life Scienc...Selected✓ RPGLIFE • 532983 | 68.7/100 | ₹2739.10₹2739 | ₹4529.79₹4529.79 | 37.86Average 37.9 Average | 20.28%Excellent 20.28% Excellent | 26.50%Excellent 26.50% Excellent | 0.03Excellent 0.0 Excellent | 23.55%Excellent 23.55% Excellent | 12.70%Good 12.70% Good | 0.81% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
RPG Life Sciences Limited PE Ratio History
Historical price-to-earnings ratio for RPGLIFE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹110.80 | ₹2322.30 | 21x |
| FY 2024 | ₹53.01 | ₹2184.45 | 41.2x |
| FY 2023 | ₹40.90 | ₹1335.85 | 32.7x |
| FY 2022 | ₹31.13 | ₹847.05 | 27.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
RPG Life Sciences Limited Dividend History
Annual cash dividends paid by RPGLIFE — dividend yield 0.81%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹26.46 Cr |
| FY 2024 | ₹19.85 Cr |
| FY 2023 | ₹15.88 Cr |
| FY 2022 | ₹11.91 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
RPG Life Sciences Limited Quarterly Performance
Latest quarterly metrics for RPGLIFE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.85%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.70%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
23.55%
Compounded annual net profit growth over 5 years
RPG Life Sciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for RPGLIFE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
RPG Life Sciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for RPG Life Sciences Limited (RPGLIFE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for RPG Life Sciences Limited
About RPGLIFE (RPG Life Sciences Limited)
RPG Life Sciences Ltd is a dynamic pharmaceutical entity operating on both Indian and global stages. The company's core business revolves around the creation, production, and distr...ibution of a wide array of pharmaceutical products. These include branded formulations targeting specific therapeutic needs, cost-effective generic medications ensuring wider accessibility, and the fundamental building blocks of many drugs – synthetic Active Pharmaceutical Ingredients (APIs). With a robust infrastructure and a focus on scientific advancement, RPG Life Sciences is committed to delivering high-quality healthcare solutions. Their efforts are geared towards addressing various medical needs through innovation and the efficient production of reliable pharmaceutical products. The company's API portfolio is particularly noteworthy, encompassing a range of therapeutic categories that address critical health concerns. These APIs are designed to treat a spectrum of conditions, including autoimmune disorders requiring immunosuppression, mental health challenges addressed by anti-psychotics, and cardiovascular ailments alleviated by anti-anginals. Furthermore, they produce APIs for combating parasitic infections with anthelmintics, managing neurological conditions with anti-convulsants, and easing muscular discomfort with anti-spasmodics. This broad spectrum of API production reflects RPG Life Sciences' dedication to supplying the pharmaceutical industry with the essential components needed to manufacture a diverse range of medications. Beyond APIs, RPG Life Sciences is also a significant player in the generics market, particularly in the realm of immunosuppressant therapy. These generic alternatives provide cost-effective treatment options for patients requiring long-term immunosuppression, often critical after organ transplantation or for managing autoimmune diseases. In addition, the company develops and distributes finished dosage formulations designed for direct patient use. These formulations cover a range of therapeutic areas, underscoring the company's commitment to providing comprehensive pharmaceutical solutions. RPG Life Sciences aims to enhance the quality of life for patients worldwide through its dedication to pharmaceutical innovation and accessibility.
Company Details
Key Leadership
RPGLIFE Share Price: Frequently Asked Questions
What is the current share price of RPG Life Sciences Limited?
RPG Life Sciences Limited (RPGLIFE) trades at ₹2739.10 on NSE and BSE. Market cap ₹4.53K (Cr). Educational data only.
What is the P/E ratio of RPG Life Sciences Limited?
RPG Life Sciences Limited has a P/E of 37.86x vs industry average 34.89x.
What is the Bull Run score for RPG Life Sciences Limited?
RPG Life Sciences Limited has a Bull Run score of 68.7/100 based on 25+ financial parameters.
Does RPG Life Sciences Limited pay dividends?
RPG Life Sciences Limited has a dividend yield of 0.81%. Past dividends don't guarantee future payments.
What is the ROE of RPG Life Sciences Limited?
RPG Life Sciences Limited has ROE of 20.28%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of RPG Life Sciences Limited?
RPG Life Sciences Limited has debt-to-equity of 0.03.
Is RPG Life Sciences Limited a good investment?
Bull Run gives RPG Life Sciences Limited a score of 68.7/100. This is not investment advice — consult a SEBI-registered advisor.